Agilent Technologies Inc. announced the opening of the Shanghai Institute of Biological Sciences (SIBS)-Agilent Centre for Systems Biology in Shanghai, China. The centre will feature multiple technology platforms in the areas of genomics, proteomics and metabolomics to conduct biomarker identification to better understand diseases.
“As a leading provider of bio-analytical instruments, Agilent is very proud to be collaborating with world-class life science researchers who are contributing to breakthrough research in China,” said Nick Roelofs, president of Agilent’s Life Sciences Group. “China has demonstrated tremendous progress in recent years in technological advancement and research capabilities and is a key focus area for Agilent’s Life Sciences Group.”
SIBS and Agilent signed an agreement in 2008 to establish the joint SIBS-Agilent Centre for System Biology. Initial work of SIBS researchers involved using Agilent chromatin immunoprecipitation-on-chip (ChIP-on-chip) and gene expression microarrays to study molecules known as “Yamanaka factors.” The research achieved new insight into how adult cells can be induced to act like embryonic stem cells (ESC), with the ability to form any type of tissue known as “pluripotency.” The findings were published in an article titled “Yamanaka factors critically regulate the developmental signalling network in mouse embryonic stem cells” (Cell Research, 2008 18:1177-1189).
“This is more than a simple technical collaboration. It is an opportunity for scientists in China to work together with a company providing advanced technologies,” said Prof. Wu Jiarui, vice president of SIBS and director of Key Laboratory of Systems Biology. “Agilent not only provides us with the technology tools, but we also look forward to close interaction with their scientists and the life science community in China. I am confident this collaboration will be a tremendous success.”